Survivin expression in oral squamous cell carcinoma

Sanamed Pub Date : 2023-01-01 DOI:10.5937/sanamed0-45111
Marija Antunović, Janja Raonić
{"title":"Survivin expression in oral squamous cell carcinoma","authors":"Marija Antunović, Janja Raonić","doi":"10.5937/sanamed0-45111","DOIUrl":null,"url":null,"abstract":"Introduction: Survivin functions as an apoptosis inhibitor and a regulator of cell division. This study aimed to determine the correlation between survivin expression and clinicopathologic parameters of oral squamous cell carcinoma (OSCC) and determine its potential role in the progression/prognosis of this type of tumor. Materials and methods: Immunohistochemical analysis of survivin expression was performed on 45 surgically obtained paraffin-embedded tissue samples of OSCCs. Data on patients' gender, age, tumor grade, site and stage, disease recurrence, metastasis occurrence , and disease-free interval (DFI) were correlated to survivin expression. Results: Survivin immunoreactivity was observed in 77.8% of samples. No significant correlation between survivin expression and age (p = 0.087), gender (p = 0.334), tumor site (p = 0.175), presence of lymph node metastases (p = 0.201), or disease recurrence (p = 0.451) was found. Survivin expression was observed in well and moderately differentiated tumors and in all clinical stages (p = 0.139). Patients with low survivin expression had better survival rates than the group with medium and high survivin expression, i.e., there was a tendency of a shorter DFI in patients with higher expression of survivin (p = 0.065). Conclusion: There is a tendency for a shorter disease-free period in patients with higher survivin expression. These data suggest that survivin expression in OSCC may act as an additional prognostic parameter that indicates an increased proliferative tumor potential. To further validate survivin as a prognostic marker in OSCC, a study with a larger sample size along with clinical follow-up data is needed.","PeriodicalId":53269,"journal":{"name":"Sanamed","volume":"242 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sanamed","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/sanamed0-45111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Survivin functions as an apoptosis inhibitor and a regulator of cell division. This study aimed to determine the correlation between survivin expression and clinicopathologic parameters of oral squamous cell carcinoma (OSCC) and determine its potential role in the progression/prognosis of this type of tumor. Materials and methods: Immunohistochemical analysis of survivin expression was performed on 45 surgically obtained paraffin-embedded tissue samples of OSCCs. Data on patients' gender, age, tumor grade, site and stage, disease recurrence, metastasis occurrence , and disease-free interval (DFI) were correlated to survivin expression. Results: Survivin immunoreactivity was observed in 77.8% of samples. No significant correlation between survivin expression and age (p = 0.087), gender (p = 0.334), tumor site (p = 0.175), presence of lymph node metastases (p = 0.201), or disease recurrence (p = 0.451) was found. Survivin expression was observed in well and moderately differentiated tumors and in all clinical stages (p = 0.139). Patients with low survivin expression had better survival rates than the group with medium and high survivin expression, i.e., there was a tendency of a shorter DFI in patients with higher expression of survivin (p = 0.065). Conclusion: There is a tendency for a shorter disease-free period in patients with higher survivin expression. These data suggest that survivin expression in OSCC may act as an additional prognostic parameter that indicates an increased proliferative tumor potential. To further validate survivin as a prognostic marker in OSCC, a study with a larger sample size along with clinical follow-up data is needed.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Survivin在口腔鳞状细胞癌中的表达
简介:Survivin是一种细胞凋亡抑制剂和细胞分裂调节剂。本研究旨在确定survivin表达与口腔鳞状细胞癌(OSCC)临床病理参数的相关性,并确定其在口腔鳞状细胞癌进展/预后中的潜在作用。材料和方法:对45例手术获得的鳞癌石蜡包埋组织样本进行survivin表达免疫组化分析。患者的性别、年龄、肿瘤分级、部位和分期、疾病复发、转移发生、无病间期(DFI)等数据与survivin表达相关。结果:77.8%的标本有Survivin免疫反应性。survivin表达与年龄(p = 0.087)、性别(p = 0.334)、肿瘤部位(p = 0.175)、有无淋巴结转移(p = 0.201)、疾病复发(p = 0.451)无显著相关性。Survivin在中度分化肿瘤及所有临床分期中均有表达(p = 0.139)。survivin低表达组生存率高于survivin中、高表达组,survivin高表达组DFI有缩短的趋势(p = 0.065)。结论:survivin表达高的患者无病期有缩短的趋势。这些数据表明,survivin在OSCC中的表达可能作为一个额外的预后参数,表明增生性肿瘤的可能性增加。为了进一步验证survivin作为OSCC预后标志物的作用,需要更大样本量的研究以及临床随访数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
23
审稿时长
8 weeks
期刊最新文献
Benefits of breastfeedinig for mother and child Physician burnout levels and associated factors in The Covid-19 pandemic Improvement of medical waste storage procedures Early detection of acute kidney injury in preterm newborns with perinatal asphyxia using serum cystatin Differences between biochemical, hematological, and coagulation parameters among patients with mild and severe COVID-19
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1